RESUMEN
We report a rare case of a 14-year-old boy with Langerhans cell histiocytosis localized to the prepuce. The patient was treated with a topical corticosteroid followed by imiquimod cream resulting in significant clinical improvement of the lesion. Although spontaneous remission is possible, the use of imiquimod may be an effective alternative therapy in cases of cutaneous Langerhans cell histiocytosis refractory to topical corticosteroids.
Asunto(s)
Histiocitosis de Células de Langerhans , Neoplasias Cutáneas , Adolescente , Histiocitosis de Células de Langerhans/diagnóstico , Histiocitosis de Células de Langerhans/tratamiento farmacológico , Humanos , Imiquimod , Masculino , Furoato de Mometasona , Remisión EspontáneaRESUMEN
Family structure, lack of reliable information, cost, and delay are usual concerns when deciding to perform BRCA analyses. Testing breast cancer tissues with four antibodies (MS110, lys27H3, vimentin, and KI67) in addition to grade evaluation enabled us to rapidly select patients for genetic testing identification. We constituted an initial breast cancer tissue microarray, considered as a learning set, comprising 27 BRCA1 and 81 sporadic tumors. A second independent validation set of 28 BRCA1 tumors was matched to 28 sporadic tumors using the same original conditions. We investigated morphological parameters and 21 markers by immunohistochemistry. A logistic regression model was used to select the minimal number of markers providing the best model to predict BRCA1 status. The model was applied to the validation set to estimate specificity and sensibility. In the initial set, univariate analyses identified 11 markers significantly associated with BRCA1 status. Then, the best multivariate model comprised only grade 3, MS110, Lys27H3, vimentin, and KI67. When applied to the validation set, BRCA1 tumors were correctly classified with a sensitivity of 83% and a specificity of 81%. The performance of this model was superior when compared to other profiles. This study offers a new rapid and cost-effective method for the prescreening of patients at high risk of being BRCA1 mutation carriers, to guide genetic testing, and finally to provide appropriate preventive measures, advice, and treatments including targeted therapy to patients and their families.